2Thomas P,Doddoli C,Yena S,et al.VATS is an adequate oncological op- eration for stage I non-small cell lung cancer[J].Eur J Cardiothorac Surg, 2002,21 (6): 1094-1099.
3Liao ML.Non-surgical therapy for patients with advanced non-small cell lung cancer[J].Respirology, 1998,3:151 - 157.
4Pepe C,Hasan B,Winton T,et al.Adjuvant vionrelbine and cisplatin in el- derly patients:National Cancer Institute of Canada and Intergroup Study JBR[J].J Clin Oncol,2007,25:1553-1561.
5Ohe Ohashi,Kubota K.Randomized phase 111 study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabin, and cisplatin plus vinorelbine for advanced non-small-cell lung cance-r:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2): 317-323.
7Ciuleanu TE,Brodowicz T, Belani CP, et al.Ma- intenance peme-trexcd plus best suppporive care (BSC) versus placebo plus BSC:A phase III study [J].J Clin Oncol,2008,26 : 801.
8Shepherd FA,Dancey J,Ramlau R,et al.Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy [J].J Clin Oncol,2000,18 : 2095-2103.
6Baumann M, Appold S, Peterson C, et al. Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer [ J ]. Lung Cancer,2001,33 : S43-S45.
7Kong FM,Ten Haken RK,Schipper MJ,et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study [ J ]. Int J Radiat Oncol Biol Phys ,2005,63 (2) : 324-333.
8Yong Yang, Lei Xing. Optimization of radiotherapy dose time fractionation with consideration of tumor special biology [ J ]. Medical Physics ,2005,12 (32) :3666-3677.
9Fowler JF, Chappell R. Non-small lung tumors repopulate rapidly during radiation therapy[ J ]. Int J Radiat Oncol Bi- ol Phys, 2000, 46:516-517.
10Keene KS, Harman EM, Knauf DG,et al. Five-year results of a phase Ⅱ trial of hyperfractionated radiotherapy and concurrent daily cisplafin chemotherapy for stage Ⅲ non-small- cell lung cancer [ J ]. Am J Clin Oncol, 2005,28 ( 3 ) : 217- 222.
10International Agency for Research on Cancer,World Health Organization. GLOBOCAN 2012:Estimated Cancer Incidence,Mortality and prevalence worldwide in 2012 [EB/OL]. Lyon:WHO,2014. http://globocan.iarc.fr/Pages/ fact_sheets_population.aspx.
